WO2006071280B1 - Immunoglobulins comprising predominantly a ga1g1cnacman5glcnac2 glycoform - Google Patents

Immunoglobulins comprising predominantly a ga1g1cnacman5glcnac2 glycoform

Info

Publication number
WO2006071280B1
WO2006071280B1 PCT/US2005/025663 US2005025663W WO2006071280B1 WO 2006071280 B1 WO2006071280 B1 WO 2006071280B1 US 2005025663 W US2005025663 W US 2005025663W WO 2006071280 B1 WO2006071280 B1 WO 2006071280B1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
immunoglobulins
host cell
glycan
glycans
Prior art date
Application number
PCT/US2005/025663
Other languages
French (fr)
Other versions
WO2006071280A1 (en
Inventor
Tillman U Gerngross
Huijuan Li
Stefan Wildt
Original Assignee
Glycofi Inc
Tillman U Gerngross
Huijuan Li
Stefan Wildt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycofi Inc, Tillman U Gerngross, Huijuan Li, Stefan Wildt filed Critical Glycofi Inc
Priority to EP05790215A priority Critical patent/EP1831256A1/en
Priority to AU2005322617A priority patent/AU2005322617A1/en
Priority to JP2007548187A priority patent/JP2008525440A/en
Priority to CA002590441A priority patent/CA2590441A1/en
Publication of WO2006071280A1 publication Critical patent/WO2006071280A1/en
Publication of WO2006071280B1 publication Critical patent/WO2006071280B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Abstract

The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is GalGlcNAcMan5GlcNAc2.

Claims

AMENDED CLAIMS Received by the International Bureau on 16 June 2006 (16.06.2006)
1. A composition comprising a plurality of immunoglobulins, each immunoglobulin comprising at least one N-glycan attached thereto wherein the composition thereby comprises a plurality of N-glycaπs and wherein greater than 50 mole percent of said plurality of N-glycans consists essentially of GalGlcNAcMan5GlcNAc2.
2. The composition of claim 1, wherein greater than 75 mole percent of said plurality of N-glycans consists essentially of GalGlcNAcMan5GlcNAc2.
3. The composition of claim 1 , wherein greater than 90 mole percent of said plurality of N-glycans consists essentially of GalGlcNAcMan5GlcNAc2.
4. The composition of claim 1 , wherein said GalGlcNAcMan5GlcNAc2 N-glycan is present at a level from about 5 mole percent to about 50 mole percent more than the next most predominant N-glycan structure of said plurality of N-glycans,
5. The composition of claim 1, wherein said immunoglobulins exhibit decreased binding affinity for an FcγRIIb receptor.
6. The composition of claim 1, wherein said immunoglobulins exhibit increased binding affinity for an FcγRlII receptor.
7. The composition of claim 6, wherein said FcγRlII receptor is a FcγRlIIa receptor.
8. The composition of claim 6, wherein said FcγRlII receptor is a FcγRIIIb receptor.
9. The composition of claim 1 , wherein said immunoglobulins exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity.
10. The composition of claim 1 , wherein said immunoglobulins are essentially free of fucose.
11. The composition of claim 1 , wherein said immunoglobulins lack fucose.
12. The composition of claim 1, wherein said immunoglobulins bind to an antigen selected from the group consisting of growth factors, FGFR. EGFR, VΕGF, leukocyte antigens, CD20, CD33, cytokines, TNF-α and TNF-β.
13. The composition of claim 1, wherein said immunoglobulins comprise an Fc region selected from the group consisting of an IgGl, IgG2, IgG3 and IgG4 region.
14. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.
15. The pharmaceutical composition of claim 14, wherein said immunoglobulins are essentially free of fucose.
16. The pharmaceutical composition of claim 14, wherein said immunoglobulins lack fiicose.
17. The pharmaceutical composition of claim 14, wherein said immunoglobulins comprise an antibody which binds to an antigen selected from the group consisting of growth factors, FGFR, EGFR3 VEGF, leukocyte antigens, CD20, CD33, cytokines, TNF-α and TNF-β.
18. The pharmaceutical composition of claim 14, wherein said immunoglobulins comprise an Fc region selected from the group consisting of an IgGl, IgG2, IgG3 and IgG4 region.
19. A kit comprising the composition of claim 1.
20. A eukaryotic host cell comprising an exogenous gene encoding an irnmunoglobulin or fragment thereof, said eukaryotic host cell engineered or selected to express said immunoglobulin or fragment thereof, thereby producing a composition comprising a plurality of immunoglobulins, each immunoglobulin comprising at least one N-glycan attached thereto wherein the composition thereby comprises a plurality of N-glycans in which the predominant N-glycan consists essentially of GalGlcNAcMan5GlcNAc2.
21. The host cell of claim 20 wherein the host cell is a lower eukaryotic host cell.
22. A method for producing in a eukaryotic host a composition comprising a plurality of immunoglobulins, each immunoglobulin comprising at least one N-glycan attached thereto wherein the composition thereby comprises a plurality of N-glycans in which the predominant N-glycan within said plurality of N-glycans consists essentially of GalGlcNAcMan5GlcNAc2.
23. The method of claim 22 wherein the host cell is a lower eukaryotic host cell.
PCT/US2005/025663 2004-12-23 2005-07-19 Immunoglobulins comprising predominantly a ga1g1cnacman5glcnac2 glycoform WO2006071280A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP05790215A EP1831256A1 (en) 2004-12-23 2005-07-19 Immunoglobulins comprising predominantly a galglcnacman5glcnac2 glycoform
AU2005322617A AU2005322617A1 (en) 2004-12-23 2005-07-19 Immunoglobulins comprising predominantly a Ga1G1cNAcMan5GlcNAc2 glycoform
JP2007548187A JP2008525440A (en) 2004-12-23 2005-07-19 Immunoglobulin comprising mainly GalGlcNAcMan5GLcNAc2 glycoform
CA002590441A CA2590441A1 (en) 2004-12-23 2005-07-19 Immunoglobulins comprising predominantly a ga1glcnacman5glcnac2 glycoform

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63965704P 2004-12-23 2004-12-23
US63969804P 2004-12-23 2004-12-23
US60/639,698 2004-12-23
US60/639,657 2004-12-23

Publications (2)

Publication Number Publication Date
WO2006071280A1 WO2006071280A1 (en) 2006-07-06
WO2006071280B1 true WO2006071280B1 (en) 2006-08-17

Family

ID=36084254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025663 WO2006071280A1 (en) 2004-12-23 2005-07-19 Immunoglobulins comprising predominantly a ga1g1cnacman5glcnac2 glycoform

Country Status (5)

Country Link
EP (1) EP1831256A1 (en)
JP (1) JP2008525440A (en)
AU (1) AU2005322617A1 (en)
CA (1) CA2590441A1 (en)
WO (1) WO2006071280A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007205939B2 (en) 2006-01-17 2012-12-13 Synthon Biopharmaceuticals B.V. Compositions and methods for humanization and optimization of N-glycans in plants
AU2008255027B2 (en) 2007-05-14 2013-10-03 Astrazeneca Ab Methods of reducing eosinophil levels
MX2011008913A (en) * 2009-02-25 2011-09-08 Merck Sharp & Dohme Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris.
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
AU2016332900C1 (en) 2015-09-29 2024-02-01 Amgen Inc. ASGR inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1137789E (en) * 1998-12-09 2010-10-21 Phyton Holdings Llc A method for manufacturing glycoproteins having human-type glycosylation
WO2002057468A2 (en) * 2001-01-19 2002-07-25 The Dow Chemical Company Method for secretory production of glycoprotein having human-type sugar chain using plant cell
US7507573B2 (en) * 2003-11-14 2009-03-24 Vib, Vzw Modification of protein glycosylation in methylotrophic yeast

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8883483B2 (en) 2000-06-28 2014-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes

Also Published As

Publication number Publication date
JP2008525440A (en) 2008-07-17
WO2006071280A1 (en) 2006-07-06
EP1831256A1 (en) 2007-09-12
AU2005322617A1 (en) 2006-07-06
CA2590441A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
WO2006071280B1 (en) Immunoglobulins comprising predominantly a ga1g1cnacman5glcnac2 glycoform
Saxena et al. Advances in therapeutic Fc engineering–modulation of IgG-associated effector functions and serum half-life
Almagro et al. Progress and challenges in the design and clinical development of antibodies for cancer therapy
US20220389118A1 (en) Antigen-binding molecule for promoting elimination of antigens
US10494437B2 (en) Heterodimer protein composition
Satoh et al. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies
Kaneko et al. Optimizing therapeutic antibody function: progress with Fc domain engineering
US20220002431A1 (en) Bispecific antibody binding to cd20 and cd3 and uses thereof
TWI654203B (en) Antibodies with calcium-dependent antigen binding ability
JP2024038068A (en) Antigen-binding molecules that promote antigen elimination via FcγRIIB
Beck et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins
EP2552955B1 (en) Antibodies with modified affinity to fcrn that promote antigen clearance
US20190375835A1 (en) Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
EP3683317A3 (en) Anti-human cd52 immunoglobulins
Golay et al. Role of Fc core fucosylation in the effector function of IgG1 antibodies
Marusic et al. N‐glycan engineering of a plant‐produced anti‐CD20‐hIL‐2 immunocytokine significantly enhances its effector functions
JP5242382B2 (en) Polypeptide variant having effector function
JP2018511328A (en) Anti-CD303 monoclonal antibody
US20200148785A1 (en) Pd-l1 and ta-muc1 antibodies
Kang et al. An engineered human Fc variant with exquisite selectivity for FcγRIIIaV158 reveals that ligation of FcγRIIIa mediates potent antibody dependent cellular phagocytosis with GM-CSF-differentiated macrophages
RU2013133412A (en) ANTIBODIES TO P-SELECTIN AND METHODS OF APPLICATION AND IDENTIFICATION
JP2013519690A5 (en)
WO2020067541A1 (en) Antibody composition
AU2022317803A1 (en) Anti-ccr8 antibodies
KR20230078632A (en) Armed NK cells for universal cell therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2590441

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005322617

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005790215

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 4685/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007548187

Country of ref document: JP

Ref document number: 200580044453.3

Country of ref document: CN

NENP Non-entry into the national phase in:

Ref country code: DE

ENP Entry into the national phase in:

Ref document number: 2005322617

Country of ref document: AU

Date of ref document: 20050719

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005322617

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005790215

Country of ref document: EP